Bertrand TOMBAL
Université Catholique de Louvain
H-index: 84
Europe-Belgium
Top articles of Bertrand TOMBAL
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Correction to: Treatment-Related Cognitive Impairment in Patients with Prostate Cancer: Patients’ Real-World Insights for Optimizing Outcomes | Advances in Therapy | Bruce A Cowan Kara Olivier Bertrand Tombal Jeffrey S Wefel | 2024 |
Radiotherapy Combined with a Radiosensitizer for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Carcinoma In Situ Bladder Cancer: An Open-label, Single-arm … | European Urology Oncology | Vérane Achard Béatrice Fournier David D'Haese Joanna Krzystyniak Bertrand Tombal | 2024/3/30 |
Safety and effectiveness of the radium‐223–taxane treatment sequence in patients with metastatic castration‐resistant prostate cancer in a global observational study (REASSURE) | Cancer | Celestia S Higano Sabina Dizdarevic John Logue Timothy Richardson Saby George | 2024/2/10 |
Corrigendum to “Impact of Concomitant Prostate Cancer Medications on Efficacy and Safety of Relugolix Versus Leuprolide in Men With Advanced Prostate Cancer”[Clinical … | Clinical Genitourinary Cancer | Daniel J George Fred Saad Michael S Cookson Daniel R Saltzstein Ronald Tutrone | 2024 |
EORTC GUCG 2238 De-escalate: A pragmatic trial to revisit intermittent androgen-deprivation therapy in metastatic hormone-naïve prostate cancer in the era of new AR pathway … | Guillaume Grisay Fabio Turco Anna Patrikidou Enrique Gallardo Díaz Raymond S McDermott | 2024/2/1 | |
Efficacy and Safety of Radiotherapy Plus Relugolix in Men With Localized or Advanced Prostate Cancer | JAMA oncology | Daniel E Spratt Daniel J George Neal D Shore Michael S Cookson Daniel R Saltzstein | 2024/3/7 |
European Association of Nuclear Medicine Focus 5: consensus on molecular imaging and theranostics in prostate cancer | European Urology | Daniela-Elena Oprea-Lager Steven MacLennan Anders Bjartell Alberto Briganti Irene A Burger | 2024/1/1 |
Efficacy and safety of darolutamide in combination with androgen-deprivation therapy and docetaxel in European patients from the phase 3 ARASENS trial | The Oncologist | Neal D Shore Maha Hussain Fred Saad Karim Fizazi Cora N Sternberg | 2024/3/1 |
Overall survival with darolutamide vs placebo in combination with androgen-deprivation therapy (ADT) and docetaxel: A sensitivity analysis from ARASENS accounting for … | Neal D Shore Bertrand F Tombal Maha HA Hussain Fred Saad Karim Fizazi | 2024/2/1 | |
Treatment-Related Cognitive Impairment in Patients with Prostate Cancer: Patients’ Real-World Insights for Optimizing Outcomes | Bruce A Cowan Kara Olivier Bertrand Tombal Jeffrey S Wefel | 2024/2 | |
PD01-07 NATURAL HISTORY OF PN1 PROSTATE CANCER AFTER RADICAL PROSTATECTOMY: COMPETING RISK ANALYSIS FROM A LARGE MULTI-INSTITUTIONAL SERIES | The Journal of Urology | Daimantas Milonas Kaunas Lithuania Alexander Giesen Lorenzo Tosco Annouschka Laenen | 2024/5 |
Prognostic impact of prostate-specific antigen at 6 months after radiotherapy in localized prostate cancer: an individual patient data analysis of randomized trials | Journal of Clinical Oncology | Lucia Kwak Praful Ravi John G Armstrong Veronique Beckendorf Joseph L Chin | 2024/3 |
Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with … | European Urology | Fred Saad Maha HA Hussain Bertrand Tombal Karim Fizazi Cora N Sternberg | 2024/4/21 |
A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532) | European urology oncology | Bertrand F Tombal Francisco Gomez-Veiga Alvaro Gomez-Ferrer Fernando López-Campos Piet Ost | 2024/1/24 |
Validation of metastasis-free survival as a surrogate endpoint for overall survival in localized prostate cancer in the era of docetaxel for castration-resistant prostate cancer | Annals of Oncology | W Xie P Ravi M Buyse S Halabi P Kantoff | 2024/3/1 |
Impact of Concomitant Prostate Cancer Medications on Efficacy and Safety of Relugolix Versus Leuprolide in Men With Advanced Prostate Cancer | Clinical Genitourinary Cancer | Daniel J George Fred Saad Michael S Cookson Daniel R Saltzstein Ronald Tutrone | 2023/6/1 |
Prostate irradiation in men with de novo, low-volume, metastatic, castration-sensitive prostate cancer (mCSPC): Results of PEACE-1, a phase 3 randomized trial with a 2x2 design. | Alberto Bossi Stéphanie Foulon Xavier Maldonado Paul Sargos Raymond S McDermott | 2023/6/10 | |
1816P Combination treatment with radium-223 (223Ra) and enzalutamide (enza) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the REASSURE study | Annals of Oncology | B Tombal PJ Goebell ND Shore DJ George A Pinto | 2023/10/1 |
Discrete-Choice Experiment to Understand the Preferences of Patients with Hormone-Sensitive Prostate Cancer in the USA, Canada, and the UK | The Patient-Patient-Centered Outcomes Research | Juan Marcos Gonzalez Arijit Ganguli Alicia K Morgans Bertrand F Tombal Sebastien J Hotte | 2023/11 |
High-risk biochemical recurrence of locally treated prostate cancer after EMBARK. An end to decades of conventional wisdom? | Vérane Achard Bertrand Tombal | 2023/12/8 |
